Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912330197> ?p ?o ?g. }
- W2912330197 endingPage "1130" @default.
- W2912330197 startingPage "1119" @default.
- W2912330197 abstract "Background Carbapenem resistance is a growing concern. Applying a novel algorithm, we examined epidemiology and outcomes of carbapenem resistance among gram-negative pathogens in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Methods In a retrospective cohort design within the Premier Research database (2009-2016), all hospitalized adult patients with a gram-negative organism in a respiratory or blood culture specimen who fit criteria for HAP/VAP based on International Classification of Diseases, Ninth Revision, Clinical Modification, codes were included in the study. Results Among 8,969 patients with HAP/VAP, 1,059 isolates (11.8%) were carbapenem-resistant (CR) organisms. Patients with CR organisms were more likely female (41.4% vs 33.2%; P < .001) and medical admissions (33.8% vs 27.4%, P < .001) than those with carbapenem-susceptible (CS) organisms. Patients with carbapenem resistance had higher comorbidity burden than those with carbapenem susceptibility (median [interquartile range] Charlson Comorbidity Index score, 3 [1-4] vs 2 [1-4]; P < .001). Pseudomonas aeruginosa was the most common gram-negative pathogen overall (24.9%) and among CS organisms (23.5%), and was second to Stenotrophomonas maltophilia (44.0%) among CR organisms (35.3%). Acinetobacter baumannii accounted for 11.8% of CR organisms and 2.5% of CS organisms (P < .001). Patients with carbapenem resistance were more likely than those with carbapenem susceptibility to receive inappropriate empiric therapy (25.8% vs 10.0%; P < .001). Carbapenem resistance did not affect adjusted mortality (22.9% CR vs 21.6% CS) or postinfection length of stay (except among survivors of VAP), but it was associated with excess costs ($8,921; 95% CI, 3,864-13,977). Conclusions Using administrative data, our novel algorithm identified patients with pneumonia at high risk for death, consistent with HAP/VAP. Among them, carbapenem resistance occurred in 12% of all cases and was associated with substantial excess in hospital costs. Carbapenem resistance is a growing concern. Applying a novel algorithm, we examined epidemiology and outcomes of carbapenem resistance among gram-negative pathogens in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). In a retrospective cohort design within the Premier Research database (2009-2016), all hospitalized adult patients with a gram-negative organism in a respiratory or blood culture specimen who fit criteria for HAP/VAP based on International Classification of Diseases, Ninth Revision, Clinical Modification, codes were included in the study. Among 8,969 patients with HAP/VAP, 1,059 isolates (11.8%) were carbapenem-resistant (CR) organisms. Patients with CR organisms were more likely female (41.4% vs 33.2%; P < .001) and medical admissions (33.8% vs 27.4%, P < .001) than those with carbapenem-susceptible (CS) organisms. Patients with carbapenem resistance had higher comorbidity burden than those with carbapenem susceptibility (median [interquartile range] Charlson Comorbidity Index score, 3 [1-4] vs 2 [1-4]; P < .001). Pseudomonas aeruginosa was the most common gram-negative pathogen overall (24.9%) and among CS organisms (23.5%), and was second to Stenotrophomonas maltophilia (44.0%) among CR organisms (35.3%). Acinetobacter baumannii accounted for 11.8% of CR organisms and 2.5% of CS organisms (P < .001). Patients with carbapenem resistance were more likely than those with carbapenem susceptibility to receive inappropriate empiric therapy (25.8% vs 10.0%; P < .001). Carbapenem resistance did not affect adjusted mortality (22.9% CR vs 21.6% CS) or postinfection length of stay (except among survivors of VAP), but it was associated with excess costs ($8,921; 95% CI, 3,864-13,977). Using administrative data, our novel algorithm identified patients with pneumonia at high risk for death, consistent with HAP/VAP. Among them, carbapenem resistance occurred in 12% of all cases and was associated with substantial excess in hospital costs." @default.
- W2912330197 created "2019-02-21" @default.
- W2912330197 creator A5020757594 @default.
- W2912330197 creator A5026253603 @default.
- W2912330197 creator A5051255888 @default.
- W2912330197 creator A5078840423 @default.
- W2912330197 creator A5090909661 @default.
- W2912330197 date "2019-06-01" @default.
- W2912330197 modified "2023-10-02" @default.
- W2912330197 title "A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia" @default.
- W2912330197 cites W1966076267 @default.
- W2912330197 cites W1984152908 @default.
- W2912330197 cites W1986836608 @default.
- W2912330197 cites W2022428051 @default.
- W2912330197 cites W2024354081 @default.
- W2912330197 cites W2024880400 @default.
- W2912330197 cites W2029983220 @default.
- W2912330197 cites W2041740107 @default.
- W2912330197 cites W2048550794 @default.
- W2912330197 cites W2049927822 @default.
- W2912330197 cites W2062328478 @default.
- W2912330197 cites W2095754613 @default.
- W2912330197 cites W2103077615 @default.
- W2912330197 cites W2104514728 @default.
- W2912330197 cites W2109728419 @default.
- W2912330197 cites W2113698813 @default.
- W2912330197 cites W2118348120 @default.
- W2912330197 cites W2123749188 @default.
- W2912330197 cites W2124706510 @default.
- W2912330197 cites W2125506168 @default.
- W2912330197 cites W2125699736 @default.
- W2912330197 cites W2133687691 @default.
- W2912330197 cites W2135191756 @default.
- W2912330197 cites W2148706534 @default.
- W2912330197 cites W2149689328 @default.
- W2912330197 cites W2155800098 @default.
- W2912330197 cites W2469832424 @default.
- W2912330197 cites W2473016454 @default.
- W2912330197 cites W2607194758 @default.
- W2912330197 cites W2885283443 @default.
- W2912330197 cites W3017100980 @default.
- W2912330197 cites W36177659 @default.
- W2912330197 cites W4230357700 @default.
- W2912330197 cites W4230543984 @default.
- W2912330197 doi "https://doi.org/10.1016/j.chest.2018.12.024" @default.
- W2912330197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30685333" @default.
- W2912330197 hasPublicationYear "2019" @default.
- W2912330197 type Work @default.
- W2912330197 sameAs 2912330197 @default.
- W2912330197 citedByCount "29" @default.
- W2912330197 countsByYear W29123301972019 @default.
- W2912330197 countsByYear W29123301972020 @default.
- W2912330197 countsByYear W29123301972021 @default.
- W2912330197 countsByYear W29123301972022 @default.
- W2912330197 countsByYear W29123301972023 @default.
- W2912330197 crossrefType "journal-article" @default.
- W2912330197 hasAuthorship W2912330197A5020757594 @default.
- W2912330197 hasAuthorship W2912330197A5026253603 @default.
- W2912330197 hasAuthorship W2912330197A5051255888 @default.
- W2912330197 hasAuthorship W2912330197A5078840423 @default.
- W2912330197 hasAuthorship W2912330197A5090909661 @default.
- W2912330197 hasConcept C107130276 @default.
- W2912330197 hasConcept C119060515 @default.
- W2912330197 hasConcept C126322002 @default.
- W2912330197 hasConcept C177713679 @default.
- W2912330197 hasConcept C2776315533 @default.
- W2912330197 hasConcept C2776352461 @default.
- W2912330197 hasConcept C2776685102 @default.
- W2912330197 hasConcept C2777637488 @default.
- W2912330197 hasConcept C2777914695 @default.
- W2912330197 hasConcept C2779159551 @default.
- W2912330197 hasConcept C2779443120 @default.
- W2912330197 hasConcept C501593827 @default.
- W2912330197 hasConcept C523546767 @default.
- W2912330197 hasConcept C54355233 @default.
- W2912330197 hasConcept C71924100 @default.
- W2912330197 hasConcept C86803240 @default.
- W2912330197 hasConcept C89423630 @default.
- W2912330197 hasConceptScore W2912330197C107130276 @default.
- W2912330197 hasConceptScore W2912330197C119060515 @default.
- W2912330197 hasConceptScore W2912330197C126322002 @default.
- W2912330197 hasConceptScore W2912330197C177713679 @default.
- W2912330197 hasConceptScore W2912330197C2776315533 @default.
- W2912330197 hasConceptScore W2912330197C2776352461 @default.
- W2912330197 hasConceptScore W2912330197C2776685102 @default.
- W2912330197 hasConceptScore W2912330197C2777637488 @default.
- W2912330197 hasConceptScore W2912330197C2777914695 @default.
- W2912330197 hasConceptScore W2912330197C2779159551 @default.
- W2912330197 hasConceptScore W2912330197C2779443120 @default.
- W2912330197 hasConceptScore W2912330197C501593827 @default.
- W2912330197 hasConceptScore W2912330197C523546767 @default.
- W2912330197 hasConceptScore W2912330197C54355233 @default.
- W2912330197 hasConceptScore W2912330197C71924100 @default.
- W2912330197 hasConceptScore W2912330197C86803240 @default.
- W2912330197 hasConceptScore W2912330197C89423630 @default.
- W2912330197 hasIssue "6" @default.
- W2912330197 hasLocation W29123301971 @default.
- W2912330197 hasLocation W29123301972 @default.